

PET SCAN REFERRAL



radiology SA

Patient Details

Name

DOB

Address

Phone

Medicare No.

Request For

- PET with Whole Body Diagnostic CT (Chest, Abdo, Pelvis)
- PET With Localised Diagnostic CT (please tick region/s)
- Head Neck Chest Abdo Pelvis Extremity
- PET with Non-Diagnostic CT (attenuation correction)

Clinical Details

Please tick appropriate box below for Medicare Rebate

(Include primary disease site, current/past treatment & histology if known)

Referring Doctor

Signature

Date

Copies To

MEDICARE CLINICAL INDICATIONS (For full description- please see back of referral)

BRAIN

- Alzheimer's Disease [item 61560]
 Brain Tumour [item 61538]
 Epilepsy [item 61559]

BREAST CANCER

- Staging [Stage III] [item 61524]
 Suspected metastatic or recurrent [item 61525]

CERVIX CANCER

- Primary staging [item 61571]
 Further staging [item 61575]

COLORECTAL CANCER

- Suspected residual, metastatic or recurrent [item 61541]

HEAD & NECK CANCER

- Staging new or recurrent [item 61598]
 Suspected residual [item 61604]

INFECTION & INFLAMMATION

- Gallium Supply Disruption [temp item 61527]

LYMPHOMA

- Staging new or untreated [item 61620]
 Residual [item 61622]
 Restaging [item 61628]
 Pre Stem Cell Transplant [item 61632]

LUNG

- Solitary nodule [item 61523]
 Staging NSCLC [item 61529]

MELANOMA

- Suspected metastatic or recurrent [item 61553]

OESOPHAGEAL OR GEJ CANCER

- Staging [item 61577]

OVARIAN CANCER

- Suspected residual, metastatic or recurrent [item 61565]

RARE & UNCOMMON CANCERS

- Initial staging [item 61612]

SARCOMA

- Staging [item 61640]
 Suspected residual or recurrent [item 61646]

SQUAMOUS CELL CARCINOMA

- Unknown primary [involves cervical nodes] [item 61610]

PSMA PROSTATE IMAGING

- Initial staging [item 61563]
 Restaging [item 61564]

BOOK YOUR APPOINTMENT

Phone: (08) 8402 0202
Fax: (08) 8402 0210
Email: central.district@radiologysa.com.au

Calvary Central Districts Hospital
25/37 Jarvis Road
Elizabeth Vale SA 5112

PET SPECIALISTS

Dr Chew
Dr Connolly
Dr Cooper
Dr El-Barhoun
Dr Hall
Dr Pearce

PET REBATABLE MBS CODES

BRAIN

Alzheimer's Disease	61560	Brain FDG PET for the diagnosis of Alzheimer's disease if, in consultation with a specialist, the clinical evaluation is equivocal, and Alzheimer's PET or SPECT has not been performed in the previous 12 months (Allowed 3 per lifetime).
Brain Tumour	61538	Brain FDG PET for suspected residual or recurrent malignant brain tumour on anatomical imaging, after definitive therapy (or during ongoing chemotherapy), in patients suitable for further therapy.
Epilepsy	61559	Brain FDG PET for evaluation of refractory epilepsy in patients being evaluated for surgery.

BREAST CANCER

Staging	61524	FDG PET for staging locally advanced (Stage III) breast cancer in a patient suitable for therapy.
Suspected metastatic or recurrent	61525	FDG PET for suspected metastatic or locally/regionally recurrent breast carcinoma in a patient suitable for therapy.

CERVIX CANCER

Initial staging	61571	FDG PET for staging of patients with histologically proven carcinoma of the uterine cervix at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
Further staging	61575	FDG PET for staging patients with confirmed local recurrence suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.

COLORECTAL CANCER

Suspected residual, metastatic or recurrent	61541	FDG PET following initial therapy, for suspected residual, metastatic or recurrent colorectal carcinoma in patients suitable for therapy.
---	-------	---

HEAD & NECK CANCER

Staging new or recurrent	61598	FDG PET for staging biopsy-proven newly diagnosed or recurrent head and neck cancer.
Suspected residual	61604	FDG PET for suspected residual head and neck cancer after definitive treatment, in patients suitable for therapy.

INFECTION & INFLAMMATION [Gallium Scan unable to be provided due to supply disruption]

Gallium Supply Disruption (temp code)	61527	Example uses: Fever of unknown origin, osteomyelitis, sarcoidosis, pneumoconiosis, TB, retroperitoneal fibrosis, vasculitis, endocarditis, inflammatory bowel disease or abscess, non-specific tumour imaging.
---------------------------------------	-------	--

LYMPHOMA

Staging new or untreated	61620	FDG PET for initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma.
Residual	61622	FDG PET to assess therapy response either during treatment or within three months of completing first line treatment for Hodgkin or non-Hodgkin lymphoma.
Restaging	61628	FDG PET for restaging following confirmation of Hodgkin or non-Hodgkin lymphoma recurrence.
Pre Stem Cell Transplant	61632	FDG PET to assess response to second-line chemotherapy if stem cell transplant is being considered for Hodgkin or non-Hodgkin lymphoma.

LUNG

Solitary nodule	61523	FDG PET for evaluation of a solitary pulmonary nodule considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
Staging	61529	FDG PET for staging proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.

MELANOMA

Suspected metastatic or recurrent	61553	FDG PET, following initial therapy, for suspected metastatic or recurrent melanoma in patients suitable for therapy.
-----------------------------------	-------	--

OESOPHAGEAL OR GEJ CANCER

Staging	61577	FDG PET for staging proven oesophageal or GEJ carcinoma, in patients suitable for therapy.
---------	-------	--

OVARIAN CANCER

Suspected residual, metastatic or recurrent	61565	FDG PET, following initial therapy, for suspected residual, metastatic or recurrent ovarian carcinoma in patients suitable for therapy.
---	-------	---

PROSTATE

Initial staging	61563	PSMA PET for initial staging of intermediate to high risk prostate cancer (Gleason score 7+ or PSA > 10ng/ml) in a previously untreated patient suitable for locoregional treatment with curative intent. (Allowed 1 per lifetime)
Restaging	61564	PSMA PET for restaging of recurrence in a treated patient suitable for more locoregional treatment (Allowed 2 per lifetime) a) PSA increase of 2ng/ml above the nadir after radiotherapy treatment b) Failure of PSA to fall to undetectable levels c) Rising PSA after radical prostatectomy

RARE & UNCOMMON CANCERS (incl. cancer with unknown primary)

Initial staging & management	61612	Initial staging in patients diagnosed with rare & uncommon cancers, or unknown primary, who are considered suitable for active therapy (once per cancer diagnosis). See RSA website for eligible cancers.
------------------------------	-------	---

SARCOMA

Staging	61640	FDG PET for initial staging of biopsy-proven sarcoma (excluding gastrointestinal stromal tumour), in patients considered by conventional staging to be potentially curable.
Suspected residual or recurrent	61646	FDG PET for suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after initial definitive therapy, to determine suitability for subsequent therapy with curative intent.

SQUAMOUS CELL CARCINOMA

Unknown primary [involves cervical nodes]	61610	FDG PET for metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
---	-------	--